胃癌淋巴结微转移的研究进展

doi:10.3760/cma.j.issn.1673-422X.2016.10.017

摘要/Abstract

摘要： 胃癌根治术后，尤其无淋巴结转移的早期胃癌根治术后仍有一定复发率，这促使研究者采用更敏感的方法追踪可能存在而被漏诊的转移，尤其是淋巴结微转移。随着检测技术的进步，微转移检出率明显提高。但其对胃癌分期、预后等诸多方面的影响仍有较大争议，因此，尚无共识的临床处理策略。而随着内镜技术治疗早期胃癌的兴起，如何平衡患者术后生命质量和治疗安全的关系，避免漏诊存在微转移的淋巴结，使得微转移研究更加迫切。

关键词: 胃肿瘤, 淋巴结, 肿瘤转移

Abstract: There is still a certain recurrence rate after extensive lymphadenectomy even to patients with nodenegative gastric cancer. It promotes the researchers to use a more sensitive and effective way to track tumor cells which are missed, especially lymph node micrometastases. With the development of detection technology, the diagnostic rate of micrometastasis is significantly increased. There are so many controversies about the impact of lymph node micrometastases that no consensus on the clinical treatment can be reached. In recent years, with the rise of endoscopic therapy, how to balance the relationship between the quality of life and the safety makes the research of micrometastases more urgent.

Key words: Stomach neoplasms, Lymph nodes, Neoplasm metastasis

周扬,付蔚华. 胃癌淋巴结微转移的研究进展[J]. 国际肿瘤学杂志, 2016, 43(10): 791-794.

Zhou Yang, Fu Weihua. Current status and recent advances of lymph node micrometastase in patients with gastric cancer[J]. Journal of International Oncology, 2016, 43(10): 791-794.

参考文献

［1］ Jeuck TL, Wittekind C. Gastric carcinoma: stage migration by immunohistochemically detected lymph node micrometastases［J］. Gastric Cancer, 2015, 18(1): 100108. DOI: 10.1007/s1012001403524. ［2］ Zhou Y, Yu F, Wu L, et al. Survival after gastrectomy in nodenegative gastric cancer: a review and metaanalysis of prognostic factors［J］. Med Sci Monit, 2015, 21: 19111919. DOI: 10.12659/MSM.893856. ［3］ Lee CM, Park SS, Kim JH. Current status and scope of lymph node micrometastasis in gastric cancer［J］. J Gastric Cancer, 2015, 15(1): 19. DOI: 10.5230/jgc.2015.15.1.1. ［4］陈嘉健. 乳腺癌前哨淋巴结微转移的检测与临床意义［J］. 国际肿瘤学杂志, 2008, 35(7): 502505. DOI: 10.3760/cma.j.issn.1673422X.2008.07.008. ［5］ Yoon H, Lee DH. New approaches to gastric cancer staging: beyond endoscopic ultrasound, computed tomography and positron emission tomography［J］. World J Gastroenterol, 2014, 20(38): 13783. DOI: 10.3748/wjg.v20.i38.13783. ［6］ Fukagawa T, Sasako M, Ito S, et al. The prognostic significance of isolated tumor cells in the lymph nodes of gastric cancer patients［J］. Gastric Cancer, 2010, 13(3): 191196. DOI: 10.1007/s1012001005561. ［7］ Hata M, Machi J, Mamou J, et al. Entirevolume serial histological examination for detection of micrometastases in lymph nodes of colorectal cancers［J］. Pathol Oncol Res, 2011, 17(4): 835841. DOI: 10.1007/s122530119390y. ［8］ Wang J, Yu JC, Kang WM, et al. The predictive effect of cadherin17 on lymph node micrometastasis in pN0 gastric cancer［J］. Ann Surg Oncol, 2012, 19(5): 15291534. DOI: 10.1245/s1043401121153. ［9］ Torlakovic EE, Nielsen S, Vyberg MA. Getting controls under control: the time is now for immunohistochemistry［J］. J Clin Pathol, 2015, 68(11): 879882. DOI: 10.1136/jclinpath2014202705. ［10］ Muto Y, Matubara H, Tanizawa T, et al. Rapid diagnosis of micrometastasis of gastric cancer using reverse transcription loopmediated isothermal amplification［J］. Oncol Rep, 2011, 26(4): 789794. DOI: 10.3892/or.2011.1389. ［11］ Jagric T, Ivanecz A, Horvat M, et al. Evaluation of a focused sentinel lymph node protocol in nodenegative gastric cancer patients［J］. Hepatogastroenterology, 2013, 60(125): 12311236. DOI: 10.5754/hge121167. ［12］ Wollants E, Van Ranst M. Detection of false positives with a commonly used Norovirus RTPCR primer set［J］. J Clin Virol, 2013, 56(1): 8485. DOI: 10.1016/j.jcv.2012.09.007. ［13］ Spychaa A, Murawa D, Korski K. The clinical importance of micrometastases within the lymphatic system in patients after total gastrectomy［J］. Rep Pract Oncol Radiother, 2011, 16(6): 232236. DOI: 10.1016/j.rpor.2011.08.002. ［14］ Kim JH, Park SS, Park SH. Clinical significance of immunohistochemicallyidentified lymphatic and/or blood vessel tumor invasion in gastric cancer［J］. J Surg Res, 2010, 162(2): 177183. DOI: 10.1016/j.jss.2009.07.015. ［15］ Sonoda H, Tani T. Clinical significance of molecular diagnosis for gastric cancer lymph node micrometastasis［J］. World J Gastroenterol, 2014, 20(38): 1372813733. DOI: 10.3748/wjg.v20.i38.13728. ［16］ Lee CM, Cho JM, Jang YJ, et al. Should lymph node micrometastasis be considered in node staging for gastric cancer?［J］. Ann Surg Oncol, 2015, 22(3): 765771. DOI: 10.1245/s104340144073z. ［17］ Tavares A, MonteiroSoares M, Viveiros FA, et al. Occult tumor cells in lymph nodes of patients with gastric cancer: a systematic review on their prevalence and predictive role［J］. Oncology, 2015, 89(5): 245254. DOI: 10.1159/000433543. ［18］ Lee T, Tanaka H, Ohira M, et al. Clinical impact of the extent of lymph node micrometastasis in undifferentiatedtype early gastric cancer［J］. Oncology, 2014, 86(4): 244252. DOI: 10.1159/000358803. ［19］ Li Y, Du P, Zhou Y, et al. Lymph node micrometastases is a poor prognostic factor for patients in pN0 gastric cancer: a metaanalysis of observational studies［J］. J Surg Res, 2014, 191(2): 413422. DOI: 10.1016/j.jss.2014.05.088. ［20］ Cao L, Hu X, Zhang Y, et al. Adverse prognosis of clusteredcell versus singlecell micrometastases in pN0 early gastric cancer［J］. J Surg Oncol, 2011, 103(1): 5356. DOI: 10.1002/jso.21755. ［21］ Zeng YJ, Zhang CD, Dai DQ. Impact of lymph node micrometastasis on gastric carcinoma prognosis: a metaanalysis［J］. World J Gastroenterol, 2015, 21(5): 16281635. DOI: 10.3748/wjg.v21.i5.1628. ［22］ Degiuli M, Sasako M, Ponti A, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer［J］. Br J Surg, 2014, 101(2): 2331. DOI: 10.1002/bjs.9345. ［23］ Chen XZ, Hu JK, Zhou ZG, et al. Metaanalysis of effectiveness and safety of D2 plus paraaortic lymphadenectomy for resectable gastric cancer［J］. J Am Coll Surg, 2010, 210(1): 100105. DOI: 10.1016/j.jamcollsurg.2009.09.033. ［24］ Kume K. Endoscopic therapy for early gastric cancer: standard techniques and recent advances in ESD［J］. World J Gastroenterol, 2014, 20(21): 64256432. DOI: 10.3748/wjg.v20.i21.6425. ［25］ Gotoda T, Iwasaki M, Kusano C, et al. Endoscopic resection of early gastric cancer treated by guideline and expanded National Cancer Centre criteria［J］. Br J Surg, 2010, 97(6): 868871. DOI: 10.1002/bjs.7033. ［26］ Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition［J］. Gastric Cancer, 2011, 14(2): 101112. DOI: 10.1007/s1012001100415. ［27］ Gurzu S, Jung I, Kadar Z. Aberrant metastatic behavior and particular features of early gastric cancer［J］. APMIS, 2015, 123(12): 9991006. DOI: 10.1111/apm.12469.

[1]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[2]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[3]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[4]	解淑萍, 孙亚红, 汪超. 早期肿瘤标志物联合NLR、PLR预测胃癌免疫治疗疗效[J]. 国际肿瘤学杂志, 2024, 51(3): 157-165.
[5]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[6]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹. 胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[7]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹. 结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[8]	张露, 蒋华, 林州, 马辰莺, 徐晓婷, 王利利, 周菊英. 免疫检查点抑制剂治疗复发转移性宫颈癌的疗效及预后分析[J]. 国际肿瘤学杂志, 2023, 50(8): 475-483.
[9]	邵慧芳, 王学红, 芦永福. CST1在胃癌进展中的作用机制及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 489-492.
[10]	朱思雨, 王学红, 李文茜, 刘曙. 胃癌患者血清FABP1水平及其与幽门螺杆菌感染的关系[J]. 国际肿瘤学杂志, 2023, 50(6): 336-341.
[11]	杨娅, 王慧礼, 刘艳, 郭金凤, 王春霞, 吕敏, 山长平. GCSH基因在胃癌SNU-1细胞增殖和凋亡中的作用研究[J]. 国际肿瘤学杂志, 2023, 50(5): 257-262.
[12]	凡梦思, 陆雅萍, 闫莉. 子宫内膜癌前哨淋巴结假阴性患者的临床病理特征分析[J]. 国际肿瘤学杂志, 2023, 50(5): 274-279.
[13]	全祯豪, 徐飞鹏, 黄哲, 黄先进, 陈日红, 孙开裕, 胡旭, 林琳. 沉默lncRNA FTX通过miR-22-3p/NLRP3炎症体通路抑制胃癌细胞增殖[J]. 国际肿瘤学杂志, 2023, 50(4): 202-207.
[14]	杨丽蓉, 王羽丰. 预测浆液性卵巢癌术后复发远处转移风险机器学习模型的构建[J]. 国际肿瘤学杂志, 2023, 50(4): 220-226.
[15]	曹梦清, 徐志勇, 施毓婷, 王凯. 三级淋巴结构在肿瘤免疫微环境调节和抗肿瘤治疗中的作用[J]. 国际肿瘤学杂志, 2023, 50(3): 169-173.